Beyond GLP-1 Alone: Why Combination Therapy Is the Next Obesity Breakthrough

Solo-drug GLP-1 therapy has reached an efficacy ceiling. Wegovy 2.4 mg gets you to 14.9% weight loss at 68 weeks. Wegovy HD 7.2 mg pushes that to 20.7%. Zepbound 15 mg gets you to 22.5%. Retatrutide 12 mg — the most efficacious obesity peptide ever read out in Phase 3 — hit 28.3% in TRIUMPH-1 last week, with a small extension cohort reaching 30.3% at 104 weeks. Past those numbers, adding more dose stops helping. The GI side effects spike — nausea jumps to 42% on retatrutide 12 mg, vomiting to 25%, diarrhea to 32%. Discontinuation hits 11.3%. The cost of getting another 5% weight loss out of the same molecule is patients walking away.

There's a second ceiling that doesn't show up in the headline numbers but matters clinically: muscle loss. Solo GLP-1 therapy produces 25-40% of total weight loss from lean mass rather than fat. For a healthy 35-year-old, that's tolerable. For a 65-year-old at risk of sarcopenia, that lean-mass loss is a side effect that ends up causing falls and fractures down the road. The lean-mass cost of going from 22% to 30% total weight loss is real.

Drug developers have known the ceiling problem was coming for a while. The strategic response is combination therapy: pair a GLP-1 backbone with a second mechanism that adds weight loss, improves body composition, or hits a different metabolic pathway. EASL 2026 in Barcelona delivered the strongest evidence to date that this approach actually works.

There are three kinds of combinations on the table.

First: combine two incretins in one molecule. Tirzepatide already does this — it hits both GLP-1 and GIP receptors. Retatrutide adds a third (glucagon). Survodutide and pemvidutide hit GLP-1 plus glucagon. These aren't really combinations in the traditional sense — they're multi-mechanism single molecules. They've delivered most of the obesity progress from 2022 to 2026.

Second: combine a GLP-1 with a non-incretin drug from a totally different mechanism class. This is the new frontier. Examples: pairing tirzepatide with an RNAi drug that targets the Activin E/ALK7 pathway (Arrowhead's ARO-INHBE), or with a myostatin inhibitor that preserves muscle (Lilly's bimagrumab analog, Regeneron's trevogrumab), or with an amylin analog that adds satiety through a different pathway (CagriSema = cagrilintide + semaglutide). These combinations either come as fixed-dose products like CagriSema or as add-on prescriptions where the GLP-1 stays and a second drug is layered on.

Third: combine non-incretin drugs with each other for MASH or other indications where GLP-1 isn't the central mechanism. Examples: Sagimet's denifanstat + Madrigal's Rezdiffra for MASH (FASN inhibitor + thyroid hormone receptor β agonist), or MetaVia's vanoglipel + DPP-4 inhibitor (GPR119 agonist that triggers gut hormones + a drug that extends those hormones' half-life).

The most interesting category is the second one — adding non-incretin mechanisms to existing GLP-1 therapy. That's where the data this week landed.

Arrowhead Pharmaceuticals presented Phase 1/2a interim data on ARO-INHBE at EASL 2026 in Barcelona today. ARO-INHBE is an RNA interference (RNAi) drug — meaning it shuts down a specific gene rather than blocking a receptor. The gene it targets is Activin E (INHBE), which sits in a pathway called Activin E/ALK7. The pathway regulates how fat cells store fat.

The data, in plain terms: a single high-dose injection of ARO-INHBE knocked down Activin E levels by 85% with effect lasting more than 3 months. At doses of 200 mg or higher, ARO-INHBE alone reduced liver fat by 44%. So far, modest. The headline number is what happened when Arrowhead combined ARO-INHBE with a low dose of tirzepatide (5 mg) in obese patients with type 2 diabetes. The combination doubled the weight loss and tripled the reduction in visceral fat, total fat, and liver fat compared to tirzepatide alone.

That's the single biggest combination-therapy result released in 2026 to date. It says, concretely, that adding a non-GLP-1 mechanism on top of incretin therapy can produce body composition outcomes that no GLP-1 alone has matched. The effect lasts long enough to support twice-yearly dosing, which is an entirely different pharmacology than the weekly injection routine that defines current GLP-1 use.

There's a caveat: this is Phase 1/2a data, not Phase 3. The patient numbers are small. The follow-up is short. We need to see whether the doubling and tripling holds up in larger, longer trials. But the size of the effect is striking enough that it shifts how the field will think about obesity therapy for the next 5 years.

Amylin is a hormone naturally co-secreted with insulin from pancreatic beta cells. It slows gastric emptying through a different mechanism than GLP-1, makes you feel full longer, and selectively reduces fat mass over lean mass. Three amylin drugs are in late development.

CagriSema (Novo Nordisk) is the most-advanced amylin combination. It pairs cagrilintide (a long-acting amylin analog) with semaglutide in a fixed-dose weekly injection. Phase 3 REDEFINE-1 documented 22.7% mean weight loss at 68 weeks. The FDA has the CagriSema filing under review with a decision expected late 2026. The combination matches Zepbound on weight loss (22.5%) but with a meaningfully better body composition profile — more fat lost, more muscle preserved. The catch: in head-to-head REDEFINE-4, CagriSema didn't beat tirzepatide 15 mg, so the commercial positioning is about safety and body composition rather than headline efficacy.

Amycretin (Novo Nordisk) is a single molecule that hits both GLP-1 and amylin receptors. Phase 1 data showed 22% weight loss at 36 weeks on the weekly subcutaneous form and 13% at 12 weeks on the oral form. The AMAZE Phase 3 program began recruiting May 18, 2026. Amycretin is structurally Novo's most direct strategic response to Lilly's retatrutide.

Petrelintide (Roche/Zealand Pharma) is an amylin analog acquired through a $5.3B March 2026 Roche partnership. Phase 2 data is expected through 2026 and 2027. The Roche commercial muscle behind petrelintide makes it the most-funded amylin program in the pipeline.

The amylin axis is the cleanest example of GLP-1 combination strategy that's already commercial. CagriSema gets to market in 2026; amycretin in 2028-2029; petrelintide in 2029-2030. Each adds a meaningful second mechanism to the GLP-1 backbone with body composition benefits.

Glucagon receptor activation does three things to body weight and metabolism: it raises resting energy expenditure (your body burns more calories at rest), it drives hepatic fatty-acid oxidation (your liver burns fat), and it modestly increases blood glucose if used alone. The trick is balancing the metabolic benefit with the glucose effect. Adding GLP-1 to glucagon agonism neutralizes the glucose risk and amplifies the fat-burning effect.

Three drugs have already done this as single molecules: Boehringer's survodutide (GLP-1/glucagon dual), Altimmune's pemvidutide (1:1 balanced GLP-1/glucagon), and Eli Lilly's retatrutide (GIP/GLP-1/glucagon triple). These aren't combination products in the traditional sense — they're multi-mechanism peptides. The pharmacology of adding glucagon shows up as additional weight loss (28.3% retatrutide vs 22.5% tirzepatide), substantial liver fat reduction (86% retatrutide liver-fat reduction vs ~35% with semaglutide alone), and the dysesthesia side effect that's specific to glucagon-receptor activation.

At EASL 2026 this week, pemvidutide's IMPACT Phase 2b data was selected as 'Best of EASL 2026' for the qFibrosis-measured fibrosis regression at 24 weeks plus improvements across multiple non-invasive tests. MetaVia presented Phase 1 data on its DA-1726 GLP-1/glucagon dual oxyntomodulin analog. Boehringer's survodutide SYNCHRONIZE-1 Phase 3 readout in MASH is expected late 2026. The glucagon arm has fully landed in the clinic; the next combination question is what to add on top of it.

MASH (metabolic dysfunction-associated steatohepatitis) is the indication where combination therapy is moving fastest in 2026. The field has multiple mechanisms in development and the trial design lends itself to combinations.

Madrigal's Rezdiffra (resmetirom) is the only FDA-approved MASH therapy — a thyroid hormone receptor β agonist small molecule, not a peptide. It hits the liver directly and reduces fat oxidation. EASL 2026 Day 1 today brought eight Rezdiffra posters from Madrigal, including new data on cardiovascular lipid markers and portal hypertension risk in compensated MASH cirrhosis.

Sagimet's denifanstat is a FASN (fatty acid synthase) inhibitor that blocks new fat synthesis in the liver. Sagimet presented EASL 2026 posters today on denifanstat combined with Rezdiffra — a small-molecule combination layering two distinct mechanisms.

MetaVia's vanoglipel (DA-1241) is a first-in-class GPR119 agonist that triggers your gut to release more GLP-1, GIP, and PYY hormones. Phase 2a data at AASLD November 2025 showed the combination arm with a DPP-4 inhibitor (which extends the half-life of endogenous GLP-1) outperformed vanoglipel alone on HbA1c and liver inflammation.

Galectin Therapeutics presented belapectin NAVIGATE trial data today — a galectin-3 inhibitor (carbohydrate-based, not peptide) for compensated MASH cirrhosis.

The MASH combinations are still mostly research-stage. Rezdiffra is on the shelf. Everyone else is testing whether adding a second mechanism beats their drug alone. Most of these are non-peptide combinations, but the lessons learned will inform GLP-1 + non-incretin combination strategy in obesity.

The muscle-loss problem with GLP-1 monotherapy has driven a specific category of combination drugs: myostatin inhibitors. Myostatin is a hormone that limits muscle growth. Blocking it makes muscle grow more than it would otherwise. If you combine a myostatin blocker with a GLP-1, you should keep more muscle while you lose fat.

Lilly is developing a bimagrumab analog (originally Novartis's drug) in combination with tirzepatide. Phase 2 data is expected late 2026 or 2027. Regeneron has trevogrumab in a similar combination position. These programs aim to deliver the GLP-1 weight loss benefit while preserving lean mass — particularly important for the 65+ population that has the highest obesity prevalence but also the highest sarcopenia risk.

Arrowhead's ARO-INHBE story sits next to the myostatin programs but works differently. Activin E is in the same TGF-beta superfamily as myostatin, but it operates on fat-storage capacity rather than muscle growth. The combination effect with tirzepatide that Arrowhead showed today — doubled weight loss, tripled fat reduction — is partly because ARO-INHBE makes fat cells less able to store fat, so the calorie deficit from GLP-1 produces a larger absolute weight loss.

The myostatin and Activin E pathways are part of a broader 'beyond GLP-1' strategy that addresses the body composition problem rather than just total weight loss. Body composition matters more clinically than the scale number, particularly for cardiovascular and functional outcomes.

If you're currently on a GLP-1 or considering one, here's what combination therapy means for you over the next 3-5 years.

If you're at your goal weight on Wegovy or Zepbound and tolerating it well: combination therapy probably doesn't matter for you in the near term. Your current drug is working. Stay on it. Maintenance dosing is the relevant conversation, not switching to a new combination product.

If you've plateaued before reaching your goal weight: combination therapy is the most likely route to additional progress. CagriSema (if approved late 2026) and amycretin (Phase 3 ongoing) are the closest options for a second-mechanism layer on top of GLP-1 efficacy. Retatrutide arrives 2027-2028 and isn't a combination but does deliver more weight loss through additional receptor mechanisms.

If you can't tolerate GLP-1 GI side effects: combination therapy that uses lower GLP-1 doses with a second mechanism may be more tolerable than maxing out the GLP-1 alone. Arrowhead's ARO-INHBE + low-dose tirzepatide is the obvious example — though it's 3-5 years from approval at minimum.

If you're losing too much muscle on GLP-1 therapy: the myostatin-inhibitor combination programs (Lilly bimagrumab analog, Regeneron trevogrumab) are the relevant ones to track. Phase 2 data through 2027.

If you have MASH and currently take semaglutide for it: the EASL 2026 data this week is signal-rich. Pemvidutide is the most-advanced GLP-1/glucagon competitor with strong Phase 2b liver-fibrosis data. Retatrutide MASLD Phase 3 reads out H1 2027. Combination products specific to MASH are 3-5 years out for FDA approval but Phase 2 data is starting to land.

Solo-drug GLP-1 therapy is good. Combination therapy could be much better, but most of it is still research-stage. The reality for the next two years is that the GLP-1 single-agent class will continue to dominate — Wegovy, Zepbound, Foundayo, Wegovy pill, and soon retatrutide. The first true GLP-1 combination to reach market is CagriSema (FDA decision late 2026) if Novo can convince the agency that the body-composition benefit outweighs the modestly-lower weight loss vs tirzepatide.

The Arrowhead ARO-INHBE data this week is the most exciting single combination data point of 2026, but it's Phase 1/2a. Phase 2 starts later this year; full Phase 2 readout 2028; Phase 3 + filing 2030; FDA approval 2031-2032. The combination paradigm is real and the science is convincing, but the commercial market won't see most of these drugs for another 4-7 years.

For patients today: stay on the GLP-1 that's working for you. Don't wait for combinations. The combination era is real, but you don't need to time it perfectly. When better drugs arrive, switching protocols will be available and your prescriber will guide the change.

For the field: the EASL 2026 + ASCO 2026 + ADA 2026 sequence this June will probably be the moment when 'combination therapy' moves from a strategic hypothesis to a near-term commercial reality. The mechanisms that prove out across this cycle — amylin, RNAi, myostatin, FASN, glucagon-as-multi-mechanism-single-molecule — will define obesity and MASH therapeutics through 2032. Solo GLP-1 won't disappear. It'll become the backbone that everything else builds on.